Skip to content

SIRIC ILIAD 2023-2027

Labeled for the second consecutive time in 2023 by the INCa, the ILIAD project is one of the eight SIRICs based on the Comprehensive Care Centers’ research integration model.

Organized around a research-care continuum, ILIAD brings together medical, scientific, and technological expertise while combining different disciplines.

ILIAD relies on integrated, innovative, and multidisciplinary research to detect, treat, and ensure sustainable employment for high-risk patients. Centered around the care pathway, the research conducted by ILIAD teams also focuses on patients’ life paths, incorporating issues of social inequalities and employment retention in the face of illness.

The research programs are implemented on two selected tumors as demonstrators: multiple myeloma and breast cancer.

SIRIC ILIAD Nantes Angers

Predict and characterize high-risk patients.
Develop early detection of high-risk patients to tailor treatments and offer personalized therapies.

Tumor resistance and innovative therapies. Understand the resistance of tumor ecosystems to develop and evaluate innovative therapies.
Develop tools to identify and address inequalities in cancer care and promote sustainable employment retention after cancer.
 

NEWS

SIRIC Scientific Advisory Board 2024

On 9 January 2025, the first international scientific council of SIRIC ILIAD for the period 2023-2027 was held. The purpose of the SAB (Scientific Advisory Board) is to advise and
Lire la suite  

The SIRIC ILIAD supports young researchers and the emergence of innovative projects

In June 2024, the SIRIC ILIAD launched a call for projects aimed at young researchers in biology-health or social sciences-epidemiology-public health. Spearheaded by the Junior Scientific Committee (JSC), this initiative
Lire la suite  

Save the date: ‘From biomarkers to innovative therapies in high-risk cancers’ symposium, May 27, 2025

On Tuesday, May 27, 2025, SIRIC ILIAD is organising a symposium entitled ‘From biomarkers to innovative therapies in high-risk cancers’ to coincide with the Nantes Université Scientific Days. The event
Lire la suite  

A new cyclotron co-operated by GIP ARRONAX and Curium PET France

The GIP Arronax and Curium PET France have partnered to co-operate the new 18 MeV Cyclotron. This technology will enable the production of radiopharmaceutical drugs such as Fluorine-18: “When we decided
Lire la suite  

New Certification for CLIP²-ILIAD!

The CLIP²-ILIAD (Imaging and Longitudinal Investigations to Ameliorate Decision-making) has been awarded the prestigious certification for the fourth time! This project, led by the GCS IRéCAN (Institut de Cancérologie de
Lire la suite  

Public lecture: Breast cancer & work – October 10, 2024

As part of Breast Cancer Awareness Month, SIRIC ILIAD and the Cancéropôle Grand Ouest are organizing the 4th edition of the public conference “Perspectives on Breast Cancer” on October 10,
Lire la suite